Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab

INTRODUCTION: Durvalumab after concurrent chemoradiation (cCRT) is now standard of care for unresected stage III non–small cell lung cancer (NSCLC). However, there is limited data on radiation pneumonitis (RP) with this regimen. Therefore, we assessed RP and evaluated previously validated toxicity m...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaverdian, Narek, Thor, Maria, Shepherd, Annemarie F., Offin, Michael D., Jackson, Andrew, Wu, Abraham J., Gelblum, Daphna Y., Yorke, Ellen D., Simone, Charles B., Chaft, Jamie E., Hellmann, Matthew D., Gomez, Daniel R., Rimner, Andreas, Deasy, Joseph O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333832/
https://www.ncbi.nlm.nih.gov/pubmed/32372571
http://dx.doi.org/10.1002/cam4.3113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333832/
https://www.ncbi.nlm.nih.gov/pubmed/32372571
http://dx.doi.org/10.1002/cam4.3113

Ejemplares similares